TrialArthritis & rheumatology (Hoboken, N.J.)2018

Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis.

Michael E Weinblatt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.